Merck & Co. + Simcere Pharmaceutical Group
Merck & Co.
Rahway, New Jersey · 1 relationship
Historical relationship
Joint Venture · 2011–2017
Simcere Pharmaceutical Group
Nanjing, Jiangsu · 1 relationship
Analysis
Merck & Co., acting through its MSD affiliate, and Simcere announced a framework agreement on July 21, 2011, to establish a China joint venture focused on improving access to quality medicines. The planned arrangement combined Merck's resources with Simcere's Chinese pharmaceutical capabilities in development, registration, manufacturing and sales, initially concentrating on branded products for cardiovascular and metabolic diseases. [1]
The initial portfolio was intended to combine products from both companies. Merck/MSD contributed Zocor (simvastatin), Cozaar (losartan), Renitec (enalapril) and access work around sitagliptin for type 2 diabetes, while Simcere contributed Xinta (levamlodipine) and Shufutan (rosuvastatin). The framework also contemplated co-promotion and distribution agreements and a possible second joint venture for manufacturing, subject to closing conditions and government approvals. [1] [2]
The equity structure was implemented in 2012 through Shanghai Simcere. Simcere's filing states that after additional capital injections by Simcere and MSD China, MSD held 51 percent and Simcere 49 percent; the company was renamed Simcere MSD (Shanghai) Pharmaceutical Co., Ltd., and its business included distribution and promotion of selected cardiovascular drugs in China. [3]
The relationship then shifted away from Merck control. Merck and Simcere executed a restructuring agreement in March 2015 under which Merck transferred its 51 percent ownership interest to Simcere, and Merck's 2015 Form 10-K says it deconsolidated the joint venture and recorded a $7 million net loss. Contemporary industry reporting described Simcere as taking over management and refocusing SMSD on local innovative and mature products. The documented record therefore distinguishes the original Merck-controlled joint venture from the later Simcere-controlled business, even though the dataset retains a 2017 end year for the historical relationship. [4] [5]
Participants
Continue through either entity
Rahway, New Jersey · 1 record in this database
Merck & Co., Inc. was founded in the United States on January 1, 1891, when 23-year-old George Merck established a business to distribute fine chemicals in New York City and nearby areas. The company’s official timeline records the first Merck Manual in 1899, the creation of the Merck Research Laboratory in Rahway in 1933, and the 1953 merger with Sharp & Dohme, which combined chemical research and manufacturing with pharmaceutical development and international reach. [1]
Merck’s current fact sheet identifies it as Merck in the United States and Canada and MSD elsewhere. As of December 31, 2025, it reported approximately 75,000 employees, headquarters in Rahway, New Jersey, and three businesses: pharmaceuticals, vaccines, and animal health. The same fact sheet reports 2025 revenue of $65.0 billion and research-and-development expense of $15.8 billion. [2]
The 2025 Form 10-K shows how that portfolio translates into current operations: Keytruda/Keytruda Qlex generated $31.680 billion in 2025 sales, Gardasil/Gardasil 9 generated $5.233 billion, and Animal Health generated $6.354 billion. The filing describes oncology, vaccines, cardiometabolic and respiratory medicines, diabetes, immunology, virology, and animal health as major franchises, while noting that product performance varied across them during the year. [3]
Nanjing, Jiangsu · 1 record in this database
Simcere Pharmaceutical Group says it was founded in 1995 and is an innovation- and R&D-driven pharmaceutical company headquartered in Nanjing. Its current therapeutic focus is neuroscience, oncology, autoimmune disease and anti-infection, and its operating model combines in-house research with strategic cooperation with innovative biotechnology companies and research institutes. The company’s milestone history also records the creation of a national key laboratory of translational medicine and innovative drugs and the establishment of Shanghai, Boston, Beijing and Hongqiao innovation or R&D centers. [1]
Simcere’s current product portfolio describes three Category I innovative pharmaceuticals and one imported innovative pharmaceutical developed and launched in China. The company says more than 10 products are recommended in over 50 clinical-practice guidelines or pathways and more than 45 products are included in China’s National Reimbursement Drug List. Its listed products include suvemcitug and trilaciclib in oncology, daridorexant and Sanbexin in neuroscience, iguratimod in autoimmune disease, and clulevibart and simnotrelvir/ritonavir in anti-infection. Product indications and regulatory status are product-specific, so the portfolio should not be read as a claim that every product is approved for every listed use. [2]
Simcere’s 2025 ESG report provides a current innovation measure: the group invested RMB2.076 billion in R&D, approximately 26.8 percent of revenue, managed more than 60 new-drug pipelines, added three externally licensed products and had two new-drug marketing applications accepted by China’s National Medical Products Administration. The report also describes open collaboration through a Simcere State Key Laboratory exploration project involving global experts in neurology and oncology. [3]